Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 209 of the 211 references it cites were found in a registry or an index.
Abstract
The glucagon-like peptide-1 (GLP-1) is a pleiotropic hormone well known for its incretin effect in the glucose-dependent stimulation of insulin secretion. However, GLP-1 is also produced in the brain and displays a critical role in neuroprotection and inflammation by activating the GLP-1 receptor signaling pathways. Several studies in vivo and in vitro using preclinical models of neurodegenerative diseases show that GLP-1R activation has anti-inflammatory properties. This review explores the molecular mechanistic action of GLP-1 RAS in relation to inflammation in the brain. These findings update our knowledge of the potential benefits of GLP-1RAS actions in reducing the inflammatory response. These molecules emerge as a potential therapeutic tool in treating neurodegenerative diseases and neuroinflammatory pathologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Schematic processing of proglucagon. NTS: nucleus of the solitary tract; GRPP: glicentin-related polypeptide; IP-1: intervening peptide-1; IP-2: intervening peptide-2; GLP-1: glucagon-like peptide-1; GLP-2: glucagon-like peptide-2; MPGF: major proglucagon fragment; PCSK1: prohormone convertase 1/3; PCSK2: prohormone convertase 2. Modified from [36]. Created with Biorender.com.](https://figures.cochat.ai/paper-figures/b03e4d8dfc0940aca0935cc5c49966ed/anti-inflammatory-effects-of-glp-1-receptor-activation-in-the-brain-in-figure-1.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1RAs can alleviate neuroinflammation by acting on the nervous system, thereby offering additional relief from pain in patients.6,409,410”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“GLP-1RAs play a neuroprotective role in neurons by facilitating neuronal survival and promoting neuronal growth, thereby preserving the structural and functional integrity of synapses.6,14”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1RAs are anti-inflammatory because they control the signals that immune cells send and receive.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“Although it is well established that GLP-1RA’s anti-inflammatory effects originate from their impact on immune cell signaling, additional in-depth investigation into the underlying molecular pathways is required.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1RAs may modulate inflammatory responses since GLP-1 receptors are present in immune cells such as macrophages, monocytes, and lymphocytes.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [24]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–209 of 209
Exendin-4 for Parkinson's disease
Esparza-Salazar, F. D. J., Lezama-Toledo, A. R., Rivera-Monroy, G., & Borlongan, C. V. (2021) · Brain Circulation · doi:10.4103/bc.bc_21_21 · Cited by 22
Alterations in Leptin Signaling in Amyotrophic Lateral Sclerosis (ALS)
Ferrer-Donato, Á., Contreras, A., Frago, L. M., Chowen, J. A., & Fernández-Martos, C. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910305 · Cited by 21
Alterations in metabolic biomarkers and their potential role in amyotrophic lateral sclerosis
Li, J., Cui, L., Sun, X., Shen, D., Yang, X., Liu, Q., & Liu, M. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51580 · Cited by 17
Astiz, M., Pernía, O., Barrios, V., García‐Segura, L. M., & Diz-Chaves, Y. (2016) · Neuroendocrinology · doi:10.1159/000444527 · Cited by 14
Self-citationNakane, A., Gotoh, Y., Ichihara, J., & Nagata, H. (2015) · Analytical Biochemistry · doi:10.1016/j.ab.2015.08.026 · Cited by 13
GLP-1R activation alters performance in cognitive tasks in a sex-dependent manner
Trammell, T. S., Henderson, N. L., Madkour, H. S., Stanwood, G. D., & Graham, D. L. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04910-8 · Cited by 10 · cited 1×
“Moreover, GLP-1R activation alters performance in cognitive tasks in a sex-dependent manner, since females benefit most from the acute Ex-4 treatment by enhancing the execution of the location discrimination task [100].”
BackgroundAlterations in leptin signaling in Amyotrophic Lateral Sclerosis (ALS)Preprint
Ferrer-Donato, Á., Contreras, A., Frago, L. M., Chowen, J. A., & Fernández-Martos, C. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.14.452319 · Cited by 4
Editorial: Neuroinflammation and the Visual System
Rossi, G. C. M., Wheeler‐Kingshott, C. A. M. G., & Toosy, A. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.724447 · Cited by 4
Merchenthaler (1999) · doi:10.1002/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Adamu, A., Li, S., Gao, F., & Xue, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1347987 · Cited by 564
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
“24,35 Through their interactions with GLP-1RAs, immune cell signals are modulated inside the cell.”
BackgroundInfluentialGlucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148209 · Cited by 317
“Frontiers in Immunology 08 mouse model of Alzheimer’s disease reduced the inflammatory response in the cortex by decreasing the number of activated microglia (60, 65, 107, 124, 125).”
BackgroundMozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154
“Because the health benefits of obesity treatment generally outweigh these temporary challenges,”
Metadata
- Authors
- Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F.
- Affiliations
- Universidade de Vigo (ES)
- Translational Neuroscience Research Group, Galicia Sur Health Research Institute, CIBERSAM, Hospital Álvaro Cunqueiro, Bloque Técnico, Planta 2, Sala de Investigación, Estrada Clara Campoamor, 341, 36212 Vigo, Spain
- Corresponding author
- Diz-Chaves, Yolanda
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-08-24
- Volume
- 23
- Issue
- 17
- Pages
- 9583
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9455625
- OpenAlex
- W4293001879
- Cited by
- 148
- References
- 211
- Citations by year
- 2026: 52 · 2025: 66 · 2024: 21 · 2023: 9
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Investigo Institutional repository of UVigo (Universidade de Vigo) (submittedVersion, cc-by)
- Funders
- European Union Grant Alehoop (H2020-BBIJTI-2019-887259, ED431G/02)
- Xunta de Galicia (Centro singular de Investigación de Galicia accreditation 2016–2019) (H2020-BBIJTI-2019-887259, ED431G/02)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- glucagon-like peptide-1, GLP-1 receptor, neuroinflammation, neurodegenerative diseases, neuroprotection, anti-inflammatory activity, brain, GLP-1 receptor signaling, therapeutic target
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Brain, Humans, Inflammation, Neurodegenerative Diseases, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.